Erratum: Corrigendum to “Advances in T-cell therapy for ALL” (Best Practice and Research: Clinical Haematology (2014) 27(3/4) (222–228)(S1521692614000802)(10.1016/j.beha.2014.10.014));Advances in T-cell therapy for ALL

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 3-4, 2014, Pages 222-228

  Grupp, Stephan A ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NONE   (United States)

Author keywords

acute lymphocytic leukemia; ALL chronic lymphocytic leukemia; CLL cytokine release syndrome macrophage activation syndrome chimeric antigen receptor; IL 6

Indexed keywords

TISAGENLECLEUCEL T; TOCILIZUMAB; CTL019 CHIMERIC ANTIGEN RECEPTOR; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL MIGRATION; CEREBROSPINAL FLUID; CYTOKINE RELEASE SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; MACROPHAGE ACTIVATION SYNDROME; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ADULT; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84923929344     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2016.07.001     Document Type: Erratum

References (29)

1. Z. Eshhar Tumor-specific T-bodies: towards clinical application Cancer Immunol Immunother 45 3-4 1997 131 136
2. Z. Eshhar, T. Waks, and G. Gross Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci U S A 90 2 1993 720 724
3. D.M. Barrett, N. Singh, and D.L. Porter Chimeric antigen receptor therapy for cancer Annu Rev Med 65 2014 333 347
4. M. Sadelain, I. Riviere, and R. Brentjens Targeting tumours with genetically enhanced T lymphocytes Nat Rev Cancer 3 1 2003 35 45
5. J.N. Kochenderfer, W.H. Wilson, and J.E. Janik Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 20 2010 4099 4102
6. M.L. Davila, I. Riviere, and X. Wang Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 224 2014 224ra225
7. S.A. Grupp, M. Kalos, and D. Barrett Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 16 2013 1509 1518
8. S.L. Maude, N. Frey, and P.A. Shaw Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 16 2014 1507 1517
9. D.W. Lee, J.N. Kochenderfer, and M. Stetler-Stevenson T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 2014 10.1016/S0140-6736(14)61403-3
10. R.A. Morgan, J.C. Yang, and M. Kitano Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 4 2010 843 851
11. D.L. Porter, B.L. Levine, and M. Kalos Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 8 2011 725 733
12. M. Kalos, B.L. Levine, and D.L. Porter T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia Sci Transl Med 3 95 2011 95ra73
13. M.V. Maus, S.A. Grupp, and D.L. Porter Antibody-modified T cells: CARs take the front seat for hematologic malignancies Blood 123 17 2014 2625 2635
14. J.N. Kochenderfer, M.E. Dudley, and R.O. Carpenter Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation Blood 122 25 2013 4129 4139
15. J.N. Kochenderfer, S.A. Feldman, and Y. Zhao Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J Immunother 32 7 2009 689 702
16. B.L. Levine T lymphocyte engineering ex vivo for cancer and infectious disease Expert Opin Biol Ther 8 4 2008 475 489
17. B.L. Levine, W. Bernstein, and N. Craighead Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells J Immunol 159 1997 5921 5930
18. N.P. Weng, L.D. Palmer, and B.L. Levine Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging Immunol Rev 160 1997 43 54
19. C. Berger, M.C. Jensen, and P.M. Lansdorp Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates J Clin Invest 118 1 2008 294 305
20. V. Hoyos, B. Savoldo, and C. Quintarelli Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 24 6 2010 1160 1170
21. R.G. Carroll, J.L. Riley, and B.L. Levine Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells Science 276 5310 1997 273 276
22. N. Ahmed, H.E. Heslop, and C.L. Mackall T-cell-based therapies for malignancy and infection in childhood Pediatr Clin North Am 57 1 2010 83 96
23. A. Di Stasi, B. De Angelis, and C.M. Rooney T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood 113 25 2009 6392 6402
24. G.A. Yanik, S.A. Grupp, and M.A. Pulsipher TNF receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome (IPS). A joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Children's Oncology Group (COG) study (ASCT0521) Biol Blood Marrow Transpl 2014 [In press]
25. G.A. Yanik, M.M. Horowitz, and D.J. Weisdorf Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol Biol Blood Marrow Transpl 20 6 2014 858 864
26. S.A. Grupp, N.V. Frey, and R. Aplenc T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL Blood 122 2013 67
27. S.L. Maude, D. Barrett, and D.T. Teachey Managing cytokine release syndrome associated with novel T cell-engaging therapies Cancer J 20 2 2014 119 122
28. D.T. Teachey, S.R. Rheingold, and S.L. Maude Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy Blood 121 26 2013 5154 5157
29. D.W. Lee, R. Gardner, and D.L. Porter Current concepts in the diagnosis and management of cytokine release syndrome Blood 124 2 2014 188 195